{"info": {"address1": "333 Lakeside Drive", "city": "Foster City", "state": "CA", "zip": "94404", "country": "United States", "phone": "650 574 3000", "fax": "650 522 5853", "website": "https://www.gilead.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.", "fullTimeEmployees": 17000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel P.  O'Day", "age": 58, "title": "Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 7267338, "exercisedValue": 0, "unexercisedValue": 9635551}, {"maxAge": 1, "name": "Mr. Andrew D. Dickinson", "age": 52, "title": "Exec. VP & CFO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 2935112, "exercisedValue": 0, "unexercisedValue": 5436829}, {"maxAge": 1, "name": "Ms. Deborah H. Telman", "age": 57, "title": "Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 2323080, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Johanna  Mercier", "age": 52, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 3322200, "exercisedValue": 0, "unexercisedValue": 3864125}, {"maxAge": 1, "name": "Dr. Merdad V. Parsey M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2022, "totalPay": 3074714, "exercisedValue": 0, "unexercisedValue": 3047349}, {"maxAge": 1, "name": "Ms. Sandra  Patterson", "age": 55, "title": "Sr. VP, Corp. Controller & Principal Accounting Officer", "yearBorn": 1967, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jacquie  Ross C.F.A.", "title": "VP of Investor Relations", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jyoti K. Mehra", "age": 46, "title": "Exec. VP of HR", "yearBorn": 1976, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael  Quigley Ph.D.", "title": "Sr. VP of Research Biology", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Linda Slanec Higgins Ph.D.", "age": 60, "title": "Sr. VP & Head of External Innovation", "yearBorn": 1962, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 4, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1680307200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 83.63, "open": 83.74, "dayLow": 82.97, "dayHigh": 83.93, "regularMarketPreviousClose": 83.63, "regularMarketOpen": 83.74, "regularMarketDayLow": 82.97, "regularMarketDayHigh": 83.93, "dividendRate": 3.0, "dividendYield": 0.0359, "exDividendDate": 1678752000, "payoutRatio": 0.8022, "fiveYearAvgDividendYield": 3.84, "beta": 0.398961, "trailingPE": 23.016483, "forwardPE": 11.571823, "volume": 4188688, "regularMarketVolume": 4188688, "averageVolume": 5985647, "averageVolume10days": 4295510, "averageDailyVolume10Day": 4295510, "bid": 0.0, "ask": 0.0, "bidSize": 800, "askSize": 900, "marketCap": 104626135040, "fiftyTwoWeekLow": 57.17, "fiftyTwoWeekHigh": 89.74, "priceToSalesTrailing12Months": 3.8351283, "fiftyDayAverage": 82.0128, "twoHundredDayAverage": 75.3663, "trailingAnnualDividendRate": 2.92, "trailingAnnualDividendYield": 0.0349157, "currency": "USD", "enterpriseValue": 122928406528, "profitMargins": 0.16832, "floatShares": 1245596157, "sharesOutstanding": 1248819968, "sharesShort": 15475585, "sharesShortPriorMonth": 15664418, "sharesShortPreviousMonthDate": 1677542400, "dateShortInterest": 1680220800, "sharesPercentSharesOut": 0.0124, "heldPercentInsiders": 0.00096000003, "heldPercentInstitutions": 0.8603, "shortRatio": 2.69, "shortPercentOfFloat": 0.0139, "impliedSharesOutstanding": 0, "bookValue": 17.033, "priceToBook": 4.918687, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1672444800, "earningsQuarterlyGrowth": 3.293, "netIncomeToCommon": 4592000000, "trailingEps": 3.64, "forwardEps": 7.24, "pegRatio": 4.87, "lastSplitFactor": "2:1", "lastSplitDate": 1359331200, "enterpriseToRevenue": 4.506, "enterpriseToEbitda": 9.4, "52WeekChange": 0.31729555, "SandP52WeekChange": -0.06829989, "lastDividendValue": 0.75, "lastDividendDate": 1678752000, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GILD", "underlyingSymbol": "GILD", "shortName": "Gilead Sciences, Inc.", "longName": "Gilead Sciences, Inc.", "firstTradeDateEpochUtc": 696090600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8659e669-8ec5-3b0f-9929-db5db506231f", "messageBoardId": "finmb_29002", "gmtOffSetMilliseconds": -14400000, "currentPrice": 83.78, "targetHighPrice": 115.0, "targetLowPrice": 63.0, "targetMeanPrice": 89.22, "targetMedianPrice": 90.0, "recommendationMean": 2.6, "recommendationKey": "hold", "numberOfAnalystOpinions": 23, "totalCash": 7144000000, "totalCashPerShare": 5.728, "ebitda": 13077000192, "totalDebt": 25807998976, "quickRatio": 1.061, "currentRatio": 1.285, "totalRevenue": 27281000448, "debtToEquity": 121.684, "revenuePerShare": 21.738, "returnOnAssets": 0.10462, "returnOnEquity": 0.21601999, "grossProfits": 21624000000, "freeCashflow": 6662374912, "operatingCashflow": 9072000000, "earningsGrowth": 3.333, "revenueGrowth": 0.02, "grossMargins": 0.79264, "ebitdaMargins": 0.47934, "operatingMargins": 0.40226, "financialCurrency": "USD", "trailingPegRatio": 0.5964}, "news": [{"uuid": "766b616f-80d0-3218-a7c5-9406a416e934", "title": "Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/gilead-sciences-gild-outpaces-stock-220010588.html", "providerPublishTime": 1681855210, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/UYup8AGIrn99rMsHiTllqA--~B/aD04NzY7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee", "width": 900, "height": 876, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/XhCCCM1n.mhdk3ZYrtuYVA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/d0d4ab152198da2f423d92da8a7d22ee", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD"]}, {"uuid": "32604c42-c637-3745-956b-1fe55055d6e8", "title": "Gilead Sciences (NASDAQ:GILD) Has A Pretty Healthy Balance Sheet", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/gilead-sciences-nasdaq-gild-pretty-130015127.html", "providerPublishTime": 1681822815, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/N3aSA3Jx5a3JL23DRH604w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD"]}, {"uuid": "e3ab7b4a-05c7-349c-a2b1-e4e564a97f5b", "title": "Veklury\u00ae (Remdesivir) Efficacy and Safety Profile Further Demonstrated in Vulnerable Patient Populations", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/veklury-remdesivir-efficacy-safety-profile-080000020.html", "providerPublishTime": 1681632000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/EJqdpwc75iozFIB76zKzmw--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8dc69855103dce5668b8fbaaa5449c69", "width": 480, "height": 160, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/0jaD0M6b.r9G_TV01wLMHw--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8dc69855103dce5668b8fbaaa5449c69", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD"]}, {"uuid": "9f444567-e370-3e9c-983f-e5c65a82d110", "title": "3 Dividend Stocks to Buy and Hold for the Next Decade", "publisher": "Motley Fool", "link": "https://finance.yahoo.com/m/9f444567-e370-3e9c-983f-e5c65a82d110/3-dividend-stocks-to-buy-and.html", "providerPublishTime": 1681553640, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DhflA5WlWC1iMF78B0qQ5Q--~B/aD0xNDE0O3c9MjExOTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/5e27b2dd3badeab4724c3488bb0922e3", "width": 2119, "height": 1414, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/051hhLoyGeLVZfccj_Y3Mg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/5e27b2dd3badeab4724c3488bb0922e3", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["JNJ", "ABBV", "GILD"]}, {"uuid": "b28cee60-123e-3718-b0c6-6e38a9a3d480", "title": "Gilead Sciences to Release First Quarter 2023 Financial Results on Thursday, April 27, 2023", "publisher": "Business Wire", "link": "https://finance.yahoo.com/news/gilead-sciences-release-first-quarter-200500956.html", "providerPublishTime": 1681416300, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/DRs2MiZRttUisJIAqPgRZA--~B/aD0xNjA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/dad8d85cd43208f196c6ced6f51f6b6c", "width": 480, "height": 160, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/cik.y8jRmIinrMPkOMmCYQ--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/dad8d85cd43208f196c6ced6f51f6b6c", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD"]}, {"uuid": "8fd537fa-d05b-313e-81a6-cc83a597df89", "title": "Gilead Sciences, Inc. (NASDAQ:GILD) is a favorite amongst institutional investors who own 84%", "publisher": "Simply Wall St.", "link": "https://finance.yahoo.com/news/gilead-sciences-inc-nasdaq-gild-110030952.html", "providerPublishTime": 1681383630, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/toOHA4B9c_p415zczXd3bQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb", "width": 1194, "height": 432, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/N3aSA3Jx5a3JL23DRH604w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/81245609dd3c4b1e638094086514d4fb", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD"]}, {"uuid": "8c2db8e3-d9e5-3a34-808f-76ca16f95092", "title": "Gilead Sciences (GILD) Dips More Than Broader Markets: What You Should Know", "publisher": "Zacks", "link": "https://finance.yahoo.com/news/gilead-sciences-gild-dips-more-220010009.html", "providerPublishTime": 1681336810, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/UPInF06X6fJkTqeimnpZuQ--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba", "width": 900, "height": 745, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/tlKVbaKmxwUbiS87UIMwQA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD", "^GSPC"]}, {"uuid": "3d193b3a-8225-3482-b8ac-b35a557b4e59", "title": "Gilead Sciences: 4 Questions: Global Experts Convene To Identify Key Measures to Long-Term Success in HIV", "publisher": "ACCESSWIRE", "link": "https://finance.yahoo.com/news/gilead-sciences-4-questions-global-122500384.html", "providerPublishTime": 1681302300, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/tWhjjWIurO16XdKENjpUCw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613", "width": 400, "height": 400, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/HmpdhD3tKRu5xZj6M0ekBA--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/accesswire.ca/9a66c0dbdb0b0d6f812565c9d6738613", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["GILD"]}]}